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Introduction
Dendritic cells (DCs) are the professional antigen-
presenting cells of the immune system. Their decisive
role in inducing immunity formed the rationale for
DC immunotherapy: DC loaded with tumor antigens
are injected into cancer patients to stimulate T cells to
eradicate tumors.
Aim
To improve immunotherapy against cancer, adequate
tumor specific immune monitoring is essential. Here, we
evaluate our monitoring tools to predict clinical out-
come to DC-based vaccination in melanoma patients.
Patients and methods
In our ongoing trials, HLA-A2.1 positive stage III and
IV melanoma patients are vaccinated with DC loaded
with gp100 and tyrosinase and control antigen keyhole
limpet hemocyanin (KLH). Routine monitoring con-
sisted of KLH specific responses in peripheral blood and
tumor specific response in blood and cultures from
DTH site biopsies.
Results
Upon vaccination, almost all patients showed prolifera-
tive and humoral responses to KLH. Tumor specific CD8
+ T cells are rarely detected in peripheral blood and coin-
cided with the presence of tumor specific CD8+ T cells in
DTH site cultures [1]. We show the strong predictive
v a l u eo fp r e s e n c eo ff u n c t i o n a lt u m o rs p e c i f i cC D 8 +
T cells in DIL cultures for PFS and overall survival (OS)
in metastatic melanoma patients, and show similar signif-
icant correlation for PFS in stage III melanoma patients.
Conclusion
Monitoring of KLH specific proliferative responses or
tumor-specific T cells in peripheral blood was not pre-
dictive for improved clinical outcome. Our findings
show that the presence of functional tumor-specific
T cells in DTH site biopsies predict clinical outcome.
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